natgillin/translations-raw huggingface dataset:
Therefore, no dose adjustment is required in patients with creatinine clearance above 30 ml/min.
Stoga, nije potrebna prilagodba doze u bolesnika s klirensom kreatinina većim od 30 ml/min.
Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.
Votrient je indiciran za liječenje odraslih bolesnika s određenim podtipovima uznapredovalog sarkoma mekih tkiva (STS; engl. soft tissue sarcoma) koji su prethodno primili kemoterapiju za metastatsku bolest ili su imali progresiju unutar 12 mjeseci nakon (neo)adjuvantne terapije.
Dosing recommendations in hepatically impaired patients are based on pharmacokinetic studies of pazopanib in patients with varying degrees of hepatic dysfunction (see section 5.2).
Preporuke za doziranje u bolesnika s oštećenjem jetre se temelje na farmakokinetičkim ispitivanjima pazopaniba u bolesnika s različitim stupnjevima poremećaja funkcije jetre (vidjeti dio 5.2).
Disease characteristics at initial diagnosis and at screening were balanced between the treatment arms with the majority of patients having clear cell histology and Stage IV disease.
Svojstva bolesti pri inicijalnoj dijagnozi kao i pri probiru raspoređene su između terapijskih krakova tako da je većina bolesnika histološki imala karcinom svijetlih stanica i bolest IV stadija.
How to store Votrient
Kako čuvati Votrient
CYP3A4, P-gp, BCRP inducers
Induktori CYP3A4, P-gp-a, BCRP-a
In preclinical experiments, pazopanib dose-dependently inhibited ligand-induced auto-phosphorylation of VEGFR-2, c-Kit and PDGFR- receptors in cells.
U pretkliničkim pokusima, pazopanib je ovisno o dozi u stanicama inhibirao autofosforilaciju induciranu ligandom VEGFR-2, c-Kit i PDGFR- receptora.
Symptoms include: - loss of speech - change of vision - seizure (fits) - confusion - high blood pressure
Simptomi uključuju: - gubitak sposobnosti govora - promjene vida - napadaje - smetenost - visoki krvni tlak
Cardiac dysfunction/heart failure, heart attack
Disfunkcija srca/zatajenje srca, srčani udar
Selection of an alternative concomitant medication with no or minimal enzyme or transporter induction potential is recommended.
Preporučuje se odabir istodobne alternativne terapije lijekovima bez ili s minimalnim potencijalom stimuliranja enzima ili prijenosa.
Transaminase elevation between 3 and 8 x ULN
Porast vrijednosti transaminaza na 3-8 x GGN
In a rat male fertility study, there was no effect on mating or fertility, but decreased testicular and epididymal weights were noted with reductions in sperm production rates, sperm motility, and epididymal and testicular sperm concentrations observed at exposures 0.3 times human exposure based on AUC.
U ispitivanju muške plodnosti u štakora nije bilo učinaka na parenje ili plodnost, ali zabilježene su smanjene težine testisa i epididimisa kao i smanjenje brzine proizvodnje sperme, motilitet spermatozoida i smanjenje koncentracije sperme u epididimisu i testisima i to pri izloženosti od 0,3 puta vrijednosti izloženosti u ljudi temeljem AUC-a.
Pazopanib is an orally administered, potent multi-target tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3, platelet-derived growth factor (PDGFR) -α and -β, and stem cell factor receptor (c-KIT), with IC50 values of 10, 30, 47, 71, 84 and 74 nM, respectively.
Pazopanib je lijek za peroralnu primjenu koji je snažni višestruki inhibitor tirozin kinaze receptora vaskularnog endotelnog čimbenika rasta (VEGFR)-1, -2, i -3, receptora trombocitnog čimbenika rasta (PDGFR) -α i -β, odnosno receptora čimbenika matičnih stanica (c-KIT), s vrijednostima IC50 od 10, 30, 47, 71, 84 odnosno 74 nM.
Interstitial lung disease (ILD)/Pneumonitis
Intersticijska bolest pluća/pneumonitis
Pooled data from the pivotal STS study (VEG110727, n=369) and the supportive Phase II study (VEG20002, n=142) was evaluated in the overall evaluation of safety and tolerability of pazopanib (total safety population n=382) in subjects with STS (see section 5.1).
Združeni podaci iz ključnog ispitivanja STS-a (VEG110727, n=369) i pratećeg ispitivanja faze II (VEG20002, n=142) procijenjeni su u sveukupnoj procjeni sigurnosti i podnošljivosti pazopaniba (sveukupna populacija za procjenu sigurnosti n=382) u ispitanika s STS-om (vidjeti dio 5.1).
Results from a meta-analysis using pooled data from clinical studies with pazopanib show that ALT >3x ULN was reported in 126/895 (14%) of patients who did not use statins, compared with 11/41 (27%) of patients who had concomitant use of simvastatin (p = 0.038).
Rezultati meta-analize koji su uključili udružene podatke iz kliničkih ispitivanja s pazopanibom pokazuju da je ALT >3 x GGN zabilježen u 126/895 (14%) bolesnika koji nisu uzimali statine u usporedbi s 11/41 (27%) bolesnika koji su istodobno uzimali simvastatin (p=0,038).
Women of childbearing potential should be advised to use adequate contraception during treatment and for at least 2 weeks after the last dose of pazopanib and to avoid becoming pregnant while receiving treatment with pazopanib.
Žene reproduktivne dobi treba savjetovati da tijekom liječenja i najmanje 2 tjedna nakon posljednje doze pazopaniba koriste adekvatne metode kontracepcije i izbjegavaju trudnoću tijekom liječenja pazopanibom.
Patients (N = 435) with locally advanced and/or metastatic RCC were randomised to receive pazopanib 800 mg once daily or placebo.
Bolesnici (N = 435) s lokalno uznapredovalim i/ili metastazirajućim RCC-om randomizirani su u skupine za primanje pazopaniba 800 mg jednom dnevno ili placeba.
Pazopanib has not been studied in patients who had a history of haemoptysis, cerebral haemorrhage or clinically significant gastrointestinal (GI) haemorrhage in the past 6 months.
Pazopanib nije ispitivan u bolesnika koji tijekom proteklih šest mjeseci u anamnezi imaju hemoptizu, cerebralno krvarenje ili klinički značajno gastrointestinalno (GI) krvarenje.
Your doctor will monitor your blood pressure while you are taking Votrient.
Vaš liječnik će pratiti Vaš krvni tlak za vrijeme uzimanja lijeka Votrient.
Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis and discontinue pazopanib in patients developing ILD or pneumonitis.
Potrebno je pratiti bolesnike zbog plućnih simptoma koji upućuju na intersticijsku bolest pluća/pneumonitis te prekinuti terapiju pazopanibom u bolesnika kod kojih se razviju intersticijska bolest pluća ili pneumonitis.
Patients with only a mild indirect hyperbilirubinaemia, known or suspected Gilbert's syndrome, and elevation in ALT >3 x ULN should be managed as per the recommendations outlined for isolated ALT elevations.
Bolesnike koji imaju samo blagu indirektnu hiperbilirubinemiju, za koje se zna ili sumnja da imaju Gilbertov sindrom, i koji imaju povišene vrijednosti ALT-a >3 x GGN treba liječiti sukladno preporukama navedenim za izolirane poraste vrijednosti ALT-a.
These results indicate that the bioavailability and the rate of pazopanib oral absorption are increased after administration of the crushed tablet relative to administration of the whole tablet (see section 4.2).
Ti podaci ukazuju da se bioraspoloživost i brzina peroralne apsorpcije pazopaniba povećava nakon primjene izmrvljene tablete u usporedbi s primjenom cijele tablete (vidjeti dio 4.2).
The safety, efficacy and quality of life of pazopanib versus sunitinib was evaluated in a randomised, open-label, parallel group Phase III non-inferiority study (VEG108844).
Sigurnost, djelotvornost i kvaliteta života tijekom liječenja pazopanibom u odnosu na one tijekom liječenja sunitinibom bile su procjenjivane u randomiziranom, otvorenom ispitivanju neinferiornosti faze III s paralelnim skupinama (VEG108844).
The risks and benefits of pazopanib should be considered before beginning therapy in patients who have pre-existing cardiac dysfunction.
Potrebno je razmotriti rizike i koristi primjene pazopaniba prije započinjanja terapije u bolesnika koji imaju već postojeću disfunkciju srca.
Laboratory abnormalities were reported as adverse events less frequently by investigators than as indicated by laboratory value tables.
Poremećaje laboratorijskih vrijednosti ispitivači su, kao štetni događaj, rjeđe prijavili nego što je navedeno u tablicama laboratorijskih vrijednosti.
If pazopanib is used during pregnancy, or if the patient becomes pregnant whilst receiving pazopanib, the potential hazard to the foetus should be explained to the patient.
U slučaju da se pazopanib koristi tijekom trudnoće ili ako bolesnica zatrudni dok je na terapiji pazopanibom, bolesnici se treba objasniti moguća opasnost za fetus.
Caution is advised in patients with creatinine clearance below 30 ml/min as there is no experience of pazopanib in this patient population (see section 4.2).
Preporučuje se oprez u bolesnika s klirensom kreatinina ispod 30 ml/min jer ne postoje iskustva o primjeni pazopaniba u toj populaciji bolesnika (vidjeti dio 4.2).
Pazopanib should be administered at least 1 hour before or 2 hours after administration of short-acting antacids.
Pazopanib treba uzeti najmanje 1 sat prije ili 2 sata nakon primjene antacida kratkog djelovanja.
Co-administration with potent P-gp or BCRP inhibitors may also alter the exposure and distribution of pazopanib, including distribution into the central nervous systems (CNS).
Istovremena primjena s potentnim inhibitorima P-gp-a ili BCRP-a također može promijeniti izloženost i distribuciju pazopaniba, uključujući i distribuciju u središnji živčani sustav (SŽS).
PFS Overall Median (months) (95% CI)
PFS Svekupno Medijan (mjeseci) (95% CI)
The efficacy and safety of pazopanib in STS were evaluated in a pivotal Phase III randomised, double-blind, placebo-controlled multicentre study (VEG110727).
Sigurnost i djelotvornost pazopaniba u STS-u procijenjena je u ključnom randomiziranom, dvostruko slijepom, placebom kontroliranom multicentričnom ispitivanju faze III (VEG110727).
Not all pack sizes or tablet strengths may be available in your country.
Vaše zemlje se ne moraju nalaziti sve jačine tableta ili veličine pakiranja.
HR = hazard ratio; ITT = intent to treat; PFS = progression-free survival.
HR = omjer hazarda; ITT = namjera liječenja; PFS = preživljenje bez progresije.
Patients should be monitored until return to Grade 1 or baseline.
Bolesnike treba nadzirati sve dok se vrijednosti ne vrate na 1. stupanj ili na početnu vrijednost.
They are supplied in bottles of 30 or 60 tablets.
Pakirane su u boce s 30 ili 60 tableta.
800 mg OD 33.5
800 mg JD 33,5
Take it at least two hours after a meal, or one hour before a meal.
Uzmite ga najmanje dva sata nakon obroka ili jedan sat prije obroka.
Caution is advised in patients with creatinine clearance below 30 ml/min as there is no experience of pazopanib in this patient population.
Preporučuje se oprez u bolesnika s klirensom kreatinina nižim od 30 ml/min jer ne postoji iskustvo o primjeni pazopaniba u toj populaciji bolesnika.
Approximately half of all patients had 3 or more organs involved in their disease and most patients had the lung (74%), and/or lymph nodes (54%) as a metastatic location for disease at baseline.
Približno je polovica svih bolesnika imala 3 ili više organa zahvaćenih bolešću, te su kod većine bolesnika pluća (74%) i/ili limfni čvorovi (54%) bili sijela metastaza na početku ispitivanja.
Signs and symptoms of stroke may include: - numbness or weakness on one side of your body - difficulty talking - headache - dizziness
Znakovi i simptomi mogu uključivati: - utrnulost ili slabost jedne strane Vašeg tijela - otežan govor - glavobolju - omaglicu
Breast-feeding should be discontinued during treatment with pazopanib.
Treba prekinuti dojenje tijekom liječenja pazopanibom.
Deep vein thrombosis (DVT) and pulmonary embolism Votrient may cause blood clots in your veins, especially in your legs (deep vein thrombosis or DVT), which may also travel to your lungs (pulmonary embolism).
Votrient može uzrokovati krvne ugruške u Vašim venama, pogotovo u nogama (duboka venska tromboza ili DVT), koji mogu otići u Vaša pluća (plućna embolija).
Some medicines may affect how Votrient works or make it more likely that you'll have side effects.
Neki lijekovi mogu utjecati na to kako Votrient djeluje ili mogu povećati mogućnost pojave nuspojava.
Adverse drug reactions, all grades, which were reported in RCC and STS subjects or during the post-marketing period are listed below by MedDRA body system organ class, frequency and grade of severity.
Nuspojave svih stupnjeva, koje su prijavljene u ispitanika s RCC-om i STS-om ili nakon stavljanja lijeka u promet, su niže navedene prema MedDRA klasifikaciji organskih sustava, učestalosti i stupnju težine.
Venous thromboembolic events
Venski tromboembolijski događaji
The median overall survival (OS) data at the protocol-specified final survival analysis were 22.9 months and 20.5 months [HR = 0.91 (95% CI: 0.71, 1.16; p = 0.224)] for patients randomised to the pazopanib and placebo arms, respectively.
Medijan sveukupnog preživljenja (OS) prema protokolu definirane završne analize preživljenja bio je 22,9 mjeseci odnosno 20,5 mjeseci [HR = 0,91 (95% CI: 0,71; 1,16; p = 0,224)] za bolesnike randomizirane u skupinu s pazopanibom odnosno skupinu s placebom.
A synthetic intermediate in manufacture of pazopanib, which is also present in the final drug substance in low amounts, was not mutagenic in the Ames assay but genotoxic in the mouse lymphoma assay and in vivo mouse micronucleus assay.
Sintetički međuproizvod u proizvodnji pazopaniba, kojeg u malim količinama nalazimo i u završnom lijeku, u Amesovom testu nije bio mutagen, ali je bio genotoksičan u testu mišjeg limfoma i in vivo testu mikronukleusa miša.
Therefore, pazopanib should be administered at least two hours after food or at least one hour before food (see section 4.2).
Stoga, pazopanib treba uzimati barem dva sata nakon obroka ili barem jedan sat prije obroka (vidjeti dio 4.2).
Pazopanib is for oral use.
Pazopanib je za peroralnu primjenu.
Decreases in LVEF in subjects who had post-baseline and follow-up LVEF measurement were detected in 11% (15/140) in the pazopanib arm, compared with 3% (1/39) in the placebo arm.
Smanjenje LVEF-a, u ispitanika kojima je LVEF mjeren nakon početka ispitivanja te u periodu praćenja, zabilježeno je u 11% (15/140) bolesnika u skupini na pazopanibu, u usporedbi s 3% (1/39) onih u placebo skupini.
Very common side effects that may show up in your blood or urine tests: - increase in liver enzymes - decrease in albumin in the blood - protein in the urine - decrease in the number of blood platelets (cells that help blood to clot) - decrease in the number of white blood cells
Vrlo česte nuspojave koje se mogu pokazati u pretragama krvi ili urina: - povišenje jetrenih enzima - sniženje razine albumina u krvi - proteini u urinu - sniženje broja trombocita (stanica koje pomažu u zgrušavanju krvi) - sniženje broja bijelih krvnih stanica
Therefore, inhibitors and inducers of CYP3A4 may alter the metabolism of pazopanib.
Stoga, inhibitori ili induktori CYP3A4 mogu utjecati na metabolizam pazopaniba.
CYP3A4, P-gp, BCRP inhibitors Pazopanib is a substrate for CYP3A4, P-gp and BCRP.
Inhibitori CYP3A4, P-gp-a, BCRP-a Pazopanib je supstrat za CYP3A4, P-gp i BCRP.
These were reported as adverse events less frequently by investigators than as indicated by laboratory value tables.
Ispitivači su rjeđe prijavili kao nuspojavu nego što je navedeno u tablicama laboratorijskih vrijednosti.
If a patient receiving concomitant simvastatin develops ALT elevations, follow guidelines for pazopanib posology and discontinue simvastatin (see section 4.4).
Ukoliko bolesnik koji istodobno uzima simvastatin razvije porast vrijednosti ALT-a, slijedite smjernice za doziranje pazopaniba i ukinite simvastatin (vidjeti dio 4.4).
Very common Tumour pain
vrlo često tumorska bol
Selection of alternative concomitant medicinal products with no or minimal potential to inhibit CYP3A4, P-gp or BCRP should be considered.
Potrebno je razmotriti mogućnost istovremenih alternativnih terapija lijekovima koji ne inhibiraju ili imaju minimalni potencijal za inhibiciju CYP3A4, P-gp-a ili BCRP-a.
Thrombotic microangiopathy (TMA)
Trombotička mikroangiopatija (TMA)
Common Gingival infection 4 (1%)
Infekcije i infestacije često infekcija gingive 4 (1%)
They are supplied in bottles of 30 or 90 tablets.
Pakirane su u boce s 30 ili 90 tableta.
Continue on pazopanib with weekly monitoring of liver function until transaminases return to Grade 1 or baseline.
Nastaviti liječenje pazopanibom uz tjedno praćenje funkcije jetre sve dok se vrijednosti transaminaza ne vrate na 1. stupanj ili na početnu vrijednost.
Upon oral administration of a single pazopanib 800 mg dose to patients with solid tumours, maximum plasma concentration (Cmax) of approximately 19 ± 13 µg/ml was obtained after median 3.5 hours (range 1.0-11.9 hours) and an AUC0-∞ of approximately 650 ± 500 µg.h/ml was obtained.
Nakon peroralne primjene jedne doze pazopaniba od 800 mg u bolesnika sa solidnim tumorima, nakon medijana od 3,5 sati (raspon 1,0 do 11,9 sati) postignuta je maksimalna koncentracija u plazmi (Cmax) od približno 19 ± 13 µg/ml i AUC0-∞ od približno 650 ± 500 µg.h/ml.
If you take too many tablets, contact a doctor or pharmacist for advice.
Ako uzmete previše tableta, obratite se liječniku ili ljekarniku.
Votrient is indicated in adults for the first-line treatment of advanced renal cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.
Votrient je indiciran za odrasle kao prva linija liječenja uznapredovalog karcinoma bubrega (RCC; engl. renal cell carcinoma), te za bolesnike koji su već primili terapiju citokinima zbog uznapredovale bolesti.
HR = hazard ratio; PFS = progression-free survival;
HR = omjer hazarda; PFS = preživljenje bez progresije;
Grapefruit juice contains an inhibitor of CYP3A4 and may also increase plasma concentrations of pazopanib.
Sok grejpa sadrži inhibitor CYP3A4 i također može povećati koncentracije pazopaniba u plazmi.
800 mg OD 52.0
800 mg JD 52,0
Not known (frequency cannot be estimated from the available data): - an enlargement and weakening of a blood vessel wall or a tear in a blood vessel wall
Nepoznato (ne može se procijeniti iz dostupnih podatka): - proširenje i slabljenje stijenke krvne žile ili rascjep stijenke krvne žile (aneurizme i disekcije arterije)
Symptoms of infections may include: - fever - flu-like symptoms such as cough, tiredness and body aches that do not go away - shortness of breath and/or wheezing - pain while urinating - cuts, scrapes or wounds that are red, warm, swollen or painful Seek medical help immediately if you get any of these symptoms.
Simptomi infekcija mogu uključivati: - vrućicu - simptome nalik gripi kao što su kašalj, umor i bolovi u tijelu koji ne prolaze - nedostatak zraka i/ili piskanje - bol prilikom mokrenja - posjekotine, ogrebotine ili rane koje su crvene, tople, otečene ili bolne Odmah potražite liječničku pomoć u slučaju pojave bilo kojega od navedenih simptoma.
Therefore, activity of pazopanib is mainly dependent on parent pazopanib exposure.
Stoga, aktivnost pazopaniba uglavnom ovisi o izloženosti nepromijenjenom pazopanibu.
Do not drink grapefruit juice while you are being treated with Votrient as this may increase the chance of side effects.
Za vrijeme terapije lijekom Votrient nemojte piti sok od grejpa jer može povećati mogućnost pojave nuspojava.
Votrient can affect how well your heart pumps or can increase the likelihood of having a heart attack.
Vaše srce pumpa ili može povećati vjerojatnost srčanog udara.
Cardiac dysfunction/Heart failure
Disfunkcija srca/zatajenje srca
Patients developing PRES/RPLS should permanently discontinue treatment with pazopanib.
Bolesnici u kojih se razvije PRES/RPLS trajno trebaju prekinuti terapiju pazopanibom.
Take it at least two hours after a meal or one hour before a meal (see section 3).
Uzmite ga najmanje dva sata nakon obroka ili jedan sat prije obroka (pogledajte dio 3).
TMA has been reported in clinical studies of pazopanib as monotherapy, in combination with bevacizumab, and in combination with topotecan (see section 4.8).
Slučajevi TMA-e zabilježeni su u kliničkim ispitivanjima pazopaniba kao monoterapije, u kombinaciji s bevacizumabom i u kombinaciji s topotekanom (vidjeti dio 4.8).
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Lijek se izdaje na ograničeni recept (Vidjeti Prilog I.: Sažetak opisa svojstava lijeka, dio 4.2).
In vitro studies suggest that pazopanib is a substrate for P-gp and BCRP.
Ispitivanja in vitro ukazuju da je pazopanib supstrat za P-gp i BCRP.
Concomitant use of pazopanib and simvastatin increases the incidence of ALT elevations.
Istodobna primjena pazopaniba i simvastatina povećava incidenciju porasta vrijednosti ALT-a.
Fatal perforation events have occurred.
Zabilježeni su slučajevi perforacije sa smrtnim ishodom.
- if you have had heart failure or a heart attack.
- ako ste doživjeli zatajenje srca ili srčani udar. - ako ste doživjeli kolaps pluća.
Pazopanib doses up to 2000 mg have been evaluated in clinical studies.
U kliničkim ispitivanjima procjenjivale su se doze pazopaniba do 2000 mg.
Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with pazopanib (see section 4.6).
Ženama u reproduktivnoj dobi treba se savjetovati da izbjegavaju trudnoću tijekom liječenja pazopanibom (vidjeti dio 4.6).
In a pharmacogenetic meta-analysis of data from 31 clinical studies of pazopanib administered either as monotherapy or in combination with other agents, ALT >5 x ULN (NCI CTC Grade 3) occurred in 19% of HLA-B*57:01 allele carriers and in 10% of non-carriers.
U farmakogenetičkoj meta-analizi podataka iz 31 kliničkog ispitivanja pazopaniba primjenjenog ili u monoterapiji ili u kombinaciji s drugim lijekovima, ALT >5 x GGN (NCI CTC stupnja 3) pojavio se u 19% ispitanika nositelja alela HLA-B*57:01 i 10% ispitanika koji nisu nositelji tog alela.
In the three smallest of these 20 subgroups, the point estimate of the hazard ratio exceeded 1.25; i.e. in subjects with no prior nephrectomy (n=186, HR=1.403, 95% CI (0.955, 2.061)), baseline LDH >1.5 x ULN (n=68, HR=1.72, 95% CI (0.943, 3.139)), and MSKCC: poor risk (n=119, HR=1.472, 95% CI (0.937, 2.313)).
U tri najmanje podskupine od njih 20, procjena omjera hazarda bila je viša od 1,25; tj. u ispitanika bez ranije nefrektomije (n=186, HR=1,403, 95% CI (0,955; 2,061)), početne vrijednosti LDH >1,5 x iznad gornje granice normale (n=68, HR=1,72, 95% CI (0,943; 3,139)) i MSKCC: nizak rizik (n=119, HR=1,472, 95% CI (0,937;
The most common adverse reactions (experienced by at least 10% of the patients) of any grade in the RCC and STS trials included: diarrhoea, hair colour change, skin hypopigmentation, exfoliative rash, hypertension, nausea, headache, fatigue, anorexia, vomiting, dysgeusia, stomatitis, weight decreased, pain, elevated alanine aminotransferase and elevated aspartate aminotransferase.
Najčešće nuspojave (koje je doživjelo najmanje 10% bolesnika) bilo kojeg stupnja u ispitivanjima RCC-a i STS-a uključivale su: proljev, promjenu boje kose, hipopigmentaciju kože, osip s ljuštenjem, hipertenziju, mučninu, glavobolju, slabost, anoreksiju, povraćanje, disgeuziju, stomatitis, smanjenje tjelesne težine, bol, povišene razine alanin aminotransferaze te povišene razine aspartat aminotransferaze.
Magnesium stearate Microcrystalline cellulose Povidone (K30) Sodium starch glycolate
Jezgra tablete magnezijev stearat celuloza, mikrokristalična povidon (K30) natrijev škroboglikolat
Pazopanib should be used with caution in patients who are at increased risk of thrombotic events or who have had a history of thrombotic events.
Pazopanib treba koristiti s posebnim oprezom u bolesnika u kojih postoji povećan rizik od trombotičkih događaja ili onih koji imaju trombotičke događaje u anamnezi.
Administration of pazopanib with a high-fat or low-fat meal results in an approximately 2-fold increase in AUC and Cmax.
Uzimanje pazopaniba s obrocima s puno ili malo masti rezultiralo je približno dvostrukim povećanjem AUC i Cmax.